Patents by Inventor Duo LIN

Duo LIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Detection and analysis method for urine-modified nucleoside based on surface-enhanced resonance Raman spectroscopy
    Patent number: 10935495
    Abstract: The present invention discloses a detection and analysis method for urine-modified nucleoside based on a surface-enhanced resonance Raman spectroscopy technology. In the method, a tumor marker modified nucleoside in the urine of a normal person and a cancer patient is extracted through the specificity of borophenylic acid gel; Au colloid is taken as an enhancing substrate to detect SERRS signals; and statistical analysis is conducted by using PLS-DA algorithms to establish a diagnosis and identification model for the SERRS of the urine-modified nucleoside. The model is used to discriminate that the to-be-detected urine-modified nucleoside belongs to the normal person or the cancer patient. After PLS-DA, the surface-enhanced resonance Raman spectroscopy data of the urine-modified nucleoside of the present invention has specificity of 96.9%, sensitivity of 98.2% and accuracy of 97.6%.
    Type: Grant
    Filed: September 18, 2016
    Date of Patent: March 2, 2021
    Assignee: Fujian Normal University
    Inventors: Shangyuan Feng, Zuci Zheng, Qiwen Wang, Lan Wang, Duo Lin, Cuncheng Weng, Zufang Huang, Yongzeng Li, Rong Chen
  • DETECTION AND ANALYSIS METHOD FOR URINE-MODIFIED NUCLEOSIDE BASED ON SURFACE-ENHANCED RESONANCE RAMAN SPECTROSCOPY
    Publication number: 20200326285
    Abstract: The present invention discloses a detection and analysis method for urine-modified nucleoside based on a surface-enhanced resonance Raman spectroscopy technology. In the method, a tumor marker modified nucleoside in the urine of a normal person and a cancer patient is extracted through the specificity of borophenylic acid gel; Au colloid is taken as an enhancing substrate to detect SERRS signals; and statistical analysis is conducted by using PLS-DA algorithms to establish a diagnosis and identification model for the SERRS of the urine-modified nucleoside. The model is used to discriminate that the to-be-detected urine-modified nucleoside belongs to the normal person or the cancer patient. After PLS-DA, the surface-enhanced resonance Raman spectroscopy data of the urine-modified nucleoside of the present invention has specificity of 96.9%, sensitivity of 98.2% and accuracy of 97.6%.
    Type: Application
    Filed: September 18, 2016
    Publication date: October 15, 2020
    Applicant: Fujian Normal University
    Inventors: Shangyuan FENG, Zuci ZHENG, Qiwen WANG, Lan WANG, Duo LIN, Cuncheng WENG, Zufang HUANG, Yongzeng LI, Rong CHEN